TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Jun 30, 2024. Filed Jul 31, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Jul 31, 2024
TEVA$42.61+2.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of changes in equity
| Teva shareholders’ equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ordinary shares | |||||||||
| Number ofshares (inmillions) | Statedvalue | Additionalpaid-in capital | Retainedearnings(accumulateddeficit) | Accumulated othercomprehensive(loss) | Treasuryshares | Total Tevashareholders’equity | Non-controllinginterests | Totalequity | |
| (U.S. dollars in millions) | |||||||||
| Balance at March 31, 2024 | 1,238 | 58 | 27,796 | (13,673) | (2,775) | (4,128) | 7,278 | 265 | 7,543 |
| Net Income (loss) | (846) | (846) | (29) | (874) | |||||
| Other comprehensive income (loss) | (106) | (106) | (32) | (138) | |||||
| Issuance of Shares | * | * | * | * | |||||
| Stock-based compensation expense | 32 | 32 | 32 | ||||||
| Balance at June 30, 2024 | 1,239 | $58 | $27,829 | $(14,519) | $(2,881) | $(4,128) | $6,359 | $204 | $6,563 |
| * | Represents an amount less than 0.5 million. |
|---|
| Teva shareholders’ equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ordinary shares | |||||||||
| Number ofshares (inmillions) | Statedvalue | Additionalpaid-in capital | Retainedearnings(accumulateddeficit) | Accumulated othercomprehensive(loss) | Treasuryshares | Total Tevashareholders’equity | Non-controllinginterests | Totalequity | |
| (U.S. dollars in millions) | |||||||||
| Balance at December 31, 2023 | 1,227 | 57 | 27,807 | (13,534) | (2,697) | (4,128) | 7,506 | 620 | 8,126 |
| Net Income (loss) | (985) | (985) | (309) | (1,294) | |||||
| Other comprehensive income (loss) | (181) | (181) | (74) | (255) | |||||
| Issuance of Shares | 12 | 1 | * | 1 | 1 | ||||
| Stock-based compensation expense | 60 | 60 | — | 60 | |||||
| Proceeds from exercise of options | 6 | 6 | 6 | ||||||
| Dividend to non-controlling interests** | (18) | (18) | |||||||
| Purchase of shares from non-controlling interests*** | (45) | (3) | (48) | (16) | (64) | ||||
| Balance at June 30, 2024 | 1,239 | $58 | $27,829 | $(14,519) | $(2,881) | $(4,128) | $6,359 | $204 | $6,563 |
| * | Represents an amount less than $0.5 million. |
|---|
| ** | In connection with dividends to non-controlling interests in Teva’s joint venture in Japan. |
|---|
| *** | Purchase of shares from non-controlling interests in a Teva’s subsidiary in Switzerland. |
|---|
| Teva shareholders’ equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ordinary shares | |||||||||
| Number ofshares (inmillions) | Statedvalue | Additionalpaid-incapital | Retainedearnings(accumulateddeficit) | Accumulated othercomprehensive(loss) | Treasuryshares | Total Tevashareholders’equity | Non-controllinginterests | Total equity | |
| (U.S. dollars in millions) | |||||||||
| Balance at March 31, 2023** | 1,226 | 57 | 27,719 | (13,194) | (2,701) | (4,128) | 7,752 | 751 | 8,504 |
| Net Income (loss)** | (872) | (872) | (35) | (906) | |||||
| Other comprehensive income (loss) | 25 | 25 | (60) | (35) | |||||
| Issuance of shares | 1 | * | * | * | * | ||||
| Stock-based compensation expense | 30 | 30 | 30 | ||||||
| Balance at June 30, 2023** | 1,227 | $57 | $27,748 | $(14,066) | $(2,677) | $(4,128) | $6,936 | $656 | $7,592 |
| * | Represents an amount less than $0.5 million. |
|---|
| ** | The data presented for prior periods has been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. For additional information, see note 1c. |
|---|
| Teva shareholders’ equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ordinary shares | |||||||||
| Number ofshares (inmillions) | Statedvalue | Additionalpaid-incapital | Retainedearnings(accumulateddeficit) | Accumulated othercomprehensive(loss) | Treasuryshares | Total Tevashareholders’equity | Non-controllinginterests | Totalequity | |
| (U.S. dollars in millions) | |||||||||
| Balance at December 31, 2022** | 1,217 | 57 | 27,688 | (12,975) | (2,838) | (4,128) | 7,804 | 794 | 8,598 |
| Net Income (loss) | (1,092) | (1,092) | (68) | (1,159) | |||||
| Other comprehensive income (loss) | 161 | 161 | (69) | 92 | |||||
| Issuance of Shares | 10 | * | * | * | |||||
| Stock-based compensation expense | 62 | 62 | — | 62 | |||||
| Balance at June 30, 2023** | 1,227 | $57 | $27,748 | $(14,066) | $(2,677) | $(4,128) | $6,936 | $656 | $7,592 |
| * | Represents an amount less than $0.5 million. |
|---|
| ** | The data presented for prior periods has been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. For additional information, see note 1c. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.